Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer

被引：0
|
作者：
Lee, Jeong-Won [1 ]
Jeong, Soo Young [1 ]
Ryu, Ji Yoon [1 ]
Lee, Yoo-Young [1 ]
Esun, Paik [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
377
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Induction of anti-tumor immune responses in ovarian cancer with c-MET inhibitor Capmatinib
    Drakes, Maureen
    Mehrotra, Swati
    Potkul, Ronald
    Stack, M. Sharon
    Stiff, Patrick
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] PARP inhibitor, anti-angiogenesis, or both? Best combination for first-line ovarian cancer treatments
    Pujade-Lauraine, Eric
    ANNALS OF ONCOLOGY, 2021, 32 : S252 - S252
  • [23] Bromodomain inhibition in ovarian cancer and the tumor microenvironment to improve PARP inhibitor response
    Wilson, Andrew J.
    Hoover, Alyssa
    Harris, Whitney
    Liu, Esther
    Khabele, Dineo
    Yull, Fiona
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Combining PARP inhibitor with cMET Inhibition overcomes PARP inhibitor resistance in epithelial ovarian cancer
    Kim, Min-Je
    Lee, Shin-Wha
    Lee, Young-Jae
    Park, Su-Bin
    Kang, Dong-Woo
    Kim, Yong-Man
    CANCER RESEARCH, 2022, 82 (12)
  • [25] Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer
    Nakata, Wachiko
    Hayakawa, Yoku
    Nakagawa, Hayato
    Sakamoto, Kei
    Kinoshita, Hiroto
    Takahashi, Ryota
    Hirata, Yoshihiro
    Maeda, Shin
    Koike, Kazuhiko
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39 (06) : 1529 - 1536
  • [26] Anti-Tumor Activity of the Proteasome Inhibitor Bortezomib in Gastric Cancer
    Nakata, Wachiko
    Hayakawa, Yoku
    Nakagawa, Hayato
    Sakamoto, Kei
    Kinoshita, Hiroto
    Takahashi, Ryota
    Hirata, Yoshihiro
    Maeda, Shin
    Koike, Kazuhiko
    GASTROENTEROLOGY, 2011, 140 (05) : S674 - S674
  • [27] High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
    Li, Xia
    Li, Chenying
    Jin, Jingrui
    Wang, Jinghan
    Huang, Jiansong
    Ma, Zhixin
    Huang, Xin
    He, Xiao
    Zhou, Yile
    Xu, Yu
    Yu, Mengxia
    Huang, Shujuan
    Yan, Xiao
    Li, Fenglin
    Pan, Jiajia
    Wang, Yungui
    Yu, Yongping
    Jin, Jie
    EBIOMEDICINE, 2018, 38 : 47 - 56
  • [28] High PARP-1 expression Predicts Poor Survival in Acute Myeloid Leukemia and PARP-1 Inhibitor and SAHA-Bendamustine Hybrid Inhibitor Combination Treatment Synergistically Enhances Anti-Tumor Effects
    Li, Xia
    Li, Chenying
    Jin, Jingrui
    Wang, Jinghan
    Jin, Jie
    BLOOD, 2018, 132
  • [29] Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells
    Xiaoyun Han
    Xiugui Sheng
    Hannah M Jones
    Amanda L Jackson
    Joshua Kilgore
    Jessica E Stine
    Monica N Schointuch
    Chunxiao Zhou
    Victoria L Bae-Jump
    Journal of Hematology & Oncology, 8
  • [30] Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells
    Han, Xiaoyun
    Sheng, Xiugui
    Jones, Hannah M.
    Jackson, Amanda L.
    Kilgore, Joshua
    Stine, Jessica E.
    Schointuch, Monica N.
    Zhou, Chunxiao
    Bae-Jump, Victoria L.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
12345